Sanofi
SNY | NASDAQ
$44.34
+$1.21 (+2.81%)
At close: Oct 30, 2026, 4:00 PM ET
$44.73
+$0.39 (+0.88%)
Pre-market:
Nov 2, 2026, 4:11 AM ET
Company Profile
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
Key Executives
| Name | Position |
|---|---|
| Belen Garijo Lopez | Chief Executive Officer & Director |
| François-Xavier Roger | Executive Vice President & Chief Financial Officer |
| Veronique Jaillet | Executive VP & Interim Chief People Officer |
| Emmanuel Frenehard | Executive VP & Chief Digital Officer |
| Erik Wallström | Head of Therapeutic Area - Neurology Development |
| Fabrizio Gaudi | Head of Austrian, German & Swiss Operations |
| Houman Ashrafian | Executive VP & Head of Research & Development |
| Jamie Haney | Executive Vice President & General Counsel |
| Karin Knobe | TA Head of Rare Diseases & Rare Blood Disorders Development |
| Madeleine Roach | Executive Vice President & Head of Business Operations |
| Michael Quigley | Chief Scientific Officer & Head of Research |
| Olivier Charmeil | Executive Vice President of General Medicines |
| Olivier Klaric | Senior Vice President of Financing & Treasury |
| Pablo Sardi | TA Head of Rare & Neurologic Diseases Research |
| Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing |
| Roy Papatheodorou | Executive Vice President & General Counsel |
| Thomas Kudsk Larsen | Head of Investor Relations & General Medicines |
| Thomas Triomphe | Executive Vice President of Vaccines |
Sanofi
| Country | France |
| IPO Date | Jul 1, 2002 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 76,493 |
| CEO | Belén Garijo López |
Contact Details
46, avenue de la Grande ArmEe Paris,
IF 75017 France
Stock Details
| Ticker Symbol | SNY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001121404 |
| CUSIP Number | 80105N105 |
| ISIN Number | US80105N1054 |
| SIC Code | 2834 |
Recent News
- 2 days ago / marketbeat.comSanofi Q3 Earnings Call Highlights
- 2 days ago / benzinga.comDupixent Is Still Booming. Sanofi's CEO Is Already Planning for Life Without It
- 2 days ago / 247wallst.comRegeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
- 2 days ago / zacks.comSanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise
- 3 days ago / wsj.comSanofi CEO Sets Sights on Deals to Drive Turnaround
- 6 days ago / 247wallst.comRegeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings
- 6 days ago / seekingalpha.comSanofi: An Alluring And Balanced Mix Of Yield And Growth
- 13 days ago / seekingalpha.comSanofi: Why The Market Seems To Be Overpricing Pipeline Risk
- 13 days ago / businesswire.comScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
- 14 days ago / globenewswire.comEnable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System
Add to Watchlist
Select watchlists to add or remove SNY